When my gynaecologist Sara J Matthews at the HCA Portland Hospital gave me this news one year ago at the ripe old age of 57, I felt oddly cheerful. The mothership had not sailed. If I wanted to have another baby (I didn’t), I technically could. I was so preoccupied with this news that I didn’t ask her the one question I should have; is having one egg at this age a good thing? And if so, shouldn’t someone be trying to slow down their exit?The answer is: they are. In New York, Columbia University is trialling low-dose rapamycin, a transplant drug in women aged 35-45 on the basis that it has slowed down ovarian ageing in mice. Preliminary data from the first 34 women suggests it may do the same in humans by about 20 per cent — the next phase will eventually enrol 1,000 women.Meanwhile, a protein based on anti-Müllerian hormone (AMH), the chemical that keeps eggs in reserve, has been developed by Oviva Therapeutics, whose founder spoke of extending “the runway to menopause”; the company was bought last year by Granata Bio, which is pointing the drug first at IVF.Meanwhile, Oura says more than 100,000 women are contributing to its perimenopause research.A new wearable called Clair due to ship in January claims to track oestrogen, progesterone, LH (luteinising hormone) and FSH (follicle-stimulating hormone) continuously, without a needle. LH and FSH tell the ovary to ripen and release an egg, and tend to be used as menopause markers. The sci-fi menopause is here, but how much of it is “sci”, and how much of it is “fi”, is debatable. The pharmaceutical chargeThe UK isn’t far behind, and in certain quarters, it’s ahead. In July 2025 the medicines regulator MHRA approved a drug called elinzanetant, sold as Lynkuet, before any other regulator in the world. A once-daily pill for hot flushes that contains no hormone at all, it works by blocking two neurokinin receptors in the hypothalamus, the brain’s thermostat, which misfires when oestrogen falls. The science behind this class of drugs was done at Imperial College, where Professor Waljit Dhillo’s team showed that injecting a brain peptide called neurokinin B into pre-menopausal women gave them hot flushes; elinzanetant was a GlaxoSmithKline schizophrenia drug, abandoned in 2012 and rescued by a handful of its former scientists working out of a business park in Stevenage; Bayer paid $425 million for it in 2020.Read MoreProfessor Mary Ann Lumsden, who chaired the NICE menopause guidelines a decade ago and now sees patients at Hormone Health in Marylebone, thinks the drug is “fantastic” for women who can’t otherwise take HRT, including those with breast cancer, and it helps with sleep, though it is expensive and not widely available. “More lookalike [drugs] are coming,” she says, while pointing out that it’s far too simplistic to assume that menopause has simply moved from the ovary to the brain.“It’s not just running out of oestrogen,” she says, “it’s the fluctuations.” In the future it may be more multidisciplinary — menopause hubs, with different specialties interactingAustralian research from the 1990s showed that in perimenopause, oestrogen and FSH “fluctuate by the second” which is why hormone testing in perimenopause is “a complete waste of time”.As for whether a year of my own hormone curve on my phone or via some other wearable could change the way doctors practise, the answer, says Lumsden, is probably not. In my own private annual HRT consultations with Matthews, in addition to blood tests and an ultrasound, there was always a long chat — the latter, argues Lumsden, will always be the most important part of any consultation. “People need to have time to see patients. I think in the future it may be something more multidisciplinary — menopause hubs, with psychologists and different specialties interacting. More emphasis on lifestyle: keeping people feeling well with exercise and diet.”To drug or not to drugWhat about the drugs? On rapamycin, Lumsden is cautious. “I suspect that it’s clinical physiology,” she says, the kind of research that matters in 20 years rather than two. On the AMH drug she is blunter — the hormone reflects the follicle pool, it doesn’t protect it, and “it’s not the eggs themselves that produce the oestrogen”. What will change practice in the future, she thinks, is genomics: a personal estimate of risk, so that our chances of getting breast cancer from HRT can be better predicted.Dr Sabine Donnai, whose clinic Viavi offers the most elaborate diagnostics money can buy in London, is cautiously optimistic about our menopausal future. A standard blood test, she agrees, “captures a moment in time”. Her patients get imaging, metabolic testing, genetics and molecular markers because what interests her is not so much whether oestrogen is falling, but how a woman’s body is coping with the fall. Continuous hormone data would be “fascinating”, she says, but “measuring more doesn’t necessarily mean understanding more”.Her 10-year vision is that menopause “will no longer come as a surprise”. A woman of 38 will know her trajectory and act on her bones, heart and brain before a single symptom arrives.But back to my one egg. Is it a good thing, if we are able, to delay losing our eggs? Not necessarily. Lumsden looks to other cultures for inspiration on how we could handle menopause better, particularly to South Asia where she has travelled extensively and marvels at how women age beautifully, “comfortable in their own skin”. We are all going to live into our eighties and nineties, she points out, and we still don’t understand what hormones do to our brains. “We need to get people to cope with ageing better,” she says. “We can’t stay young forever.” Someone had better tell my (one) egg that. If it’s still there, that is.
The menopause of the future is on its way… but is it what we really want?
Full Article
Original Source
Read the full article at Standard →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.